Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) | Psychedelic Invest

NEW YORK, USA and MELBOURNE, Australia, 30 July, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial. IHL-42X comprises two drugs, dronabinol…

Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed

April 5, 2024

Biogen to halt sales and development of controversial Alzheimer’s drug Aduhelm

Biogen will stop sales and development of its controversial Alzheimer’s drug Aduhelm, walking away from a drug that was approved against outside experts’ advice, led

February 1, 2024

Opinion | ‘Is It Safe to Hit a Kid in the Head 200 Times?’: What We Heard This Week

“Is it safe to hit a kid in the head 200 times?” — Chris Nowinski, PhD, of the Concussion Legacy Foundation in Boston, on head

September 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.